Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL340399 in Advanced Solid Tumors
NCT05387928Phase 1Completed
- Sponsor
- Kelun-Biotech
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KL340399 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Started Jun 2022; status: completed.
02
Drugs
KL340399
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05387928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387928.